Opportunity Information: Apply for RFA DA 14 003
Apply for RFA DA 14 003
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Advancing Exceptional Research on HIV/AIDS (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279 Drug Abuse and Addiction Research Programs.
- This funding opportunity was created on Mar 20, 2013 and posted on Mar 20, 2013.
- Applicants must submit their applications by Aug 1, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $2,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Public housing authorities/Indian housing authorities Private institutions of higher education State governments Independent school districts Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Special district governments For profit organizations other than small businesses County governments City or township governments Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Institutes of Health (NIH) funding opportunity announcement (FOA) titled "Advancing Exceptional Research on HIV/AIDS (R01)" (Funding Opportunity Number RFA-DA-14-003) is a discretionary grant program designed to support highly innovative research at the R01 level that sits at the intersection of HIV/AIDS and drug abuse. The core aim is to push the field toward ideas and approaches that are genuinely new, with the potential to open entirely new directions in HIV/AIDS research or to create fresh avenues for preventing and treating HIV among people who use drugs. A central expectation is that applicants clearly and convincingly explain the connection to substance use or substance use-related contexts; this nexus is not optional or implied, but something reviewers should be able to see directly in the rationale, design, and anticipated impact of the project.
This FOA is positioned as a complement to NIH's Avant Garde Award Program for HIV/AIDS research. The key practical difference is that the Avant Garde mechanism emphasizes high-risk, high-reward work and does not require a detailed research plan, whereas this R01 FOA does. Applications under RFA-DA-14-003 are expected to include a well-developed, detailed research plan and preliminary data, meaning the program is looking for bold, creative science that is still grounded enough to be testable and executable within a conventional R01 structure. In other words, the FOA encourages unusually innovative concepts, but with the rigor and supporting evidence typically expected for an R01 proposal.
In terms of scientific scope, the announcement is intentionally broad. It is open to both individual investigators and collaborative research teams, and it is not restricted to a single discipline, methodological approach, or subtopic within HIV/AIDS research. The unifying requirement is innovation with relevance to HIV/AIDS in the context of drug abuse. Projects might address prevention, treatment, or other research areas so long as they plausibly advance HIV/AIDS science and produce knowledge or tools that matter for substance-using populations. The FOA explicitly emphasizes the potential to open new research areas, suggesting that transformative or field-shifting ideas are particularly valued.
Administratively, this opportunity uses the NIH R01 grant mechanism and falls under the "Education" and "Health" activity categories, with CFDA number 93.279 (Drug Abuse and Addiction Research Programs). The total estimated funding listed is $2,000,000, and there is no cost sharing or matching requirement, which is consistent with many NIH research grant opportunities. The FOA was posted on March 20, 2013, with an original and current closing date of August 1, 2013, and an archive date of September 1, 2013, indicating the solicitation is historical rather than currently open.
Eligibility is broad and inclusive across many organization types. Eligible applicants include a wide range of U.S.-based entities such as public and private institutions of higher education, nonprofits (including those with and without 501(c)(3) status, with certain distinctions), small businesses and other for-profit organizations (with limits depending on category), and multiple levels of government including state, county, city/township, special district governments, and school districts. The eligibility list also extends to tribal entities, including federally recognized tribal governments and tribal organizations that are not federally recognized, and it explicitly includes institutions and organizations serving specific populations, such as HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISIS-designated institutions. Importantly, the FOA allows participation by non-U.S. entities as well: foreign organizations and foreign institutions may apply, non-domestic components of U.S. organizations are eligible, and foreign components as defined by NIH policy are allowed. It also includes U.S. territories and possessions and regional organizations, reflecting NIH's broad approach to building global and cross-jurisdictional capacity in HIV and substance use research.
For applicants seeking official details, the full announcement was made available through an NIH Grants Guide link (http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-14-003.html). The contact information provided is routed through the NIH Office of Extramural Research (OER) Webmaster for access or linking issues (FBOWebmaster@OD.NIH.GOV), which indicates the excerpted listing is primarily a summary and that the detailed instructions, review considerations, and policy requirements would be found in the full FOA text.
Overall, this FOA is best understood as NIH's attempt to fund unusually forward-looking HIV/AIDS research that is explicitly relevant to drug abuse, using the standard R01 structure to ensure projects are supported by preliminary evidence and a concrete plan. It encourages high-impact innovation, but expects applicants to demonstrate feasibility and to articulate clearly why the work matters specifically for HIV prevention and treatment among substance-using populations.
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The funding opportunity announcement (FOA) is titled "Advancing Exceptional Research on HIV/AIDS (R01)."
What is the Funding Opportunity Number?
The Funding Opportunity Number is RFA-DA-14-003.
What type of grant mechanism does this FOA use?
This FOA uses the NIH R01 grant mechanism.
What is the main purpose of this FOA?
The FOA is designed to support highly innovative R01-level research at the intersection of HIV/AIDS and drug abuse, with the goal of pushing the field toward genuinely new ideas and approaches that could open new directions in HIV/AIDS research or create new avenues for preventing and treating HIV among people who use drugs.
Is a connection to drug abuse required, or just encouraged?
A clear and convincing connection to substance use or substance use-related contexts is a central expectation. The nexus to drug abuse is not optional or implied; reviewers should be able to see it directly in the project rationale, design, and anticipated impact.
What kinds of research topics are allowed under this FOA?
The scientific scope is intentionally broad. Projects may address prevention, treatment, or other HIV/AIDS research areas, as long as they are innovative and plausibly advance HIV/AIDS science in ways that matter for substance-using populations.
Does the FOA restrict applicants to specific disciplines or methods?
No. The announcement is not restricted to a single discipline, methodological approach, or subtopic. The unifying requirement is innovation with relevance to HIV/AIDS in the context of drug abuse.
Does this FOA support individual investigators, teams, or both?
It is open to both individual investigators and collaborative research teams.
How does this FOA relate to the NIH Avant Garde Award Program for HIV/AIDS research?
This FOA is positioned as a complement to the NIH Avant Garde Award Program. A key practical difference described is that the Avant Garde mechanism emphasizes high-risk, high-reward research and does not require a detailed research plan, whereas this R01 FOA does require a well-developed, detailed plan.
Does this R01 FOA require a detailed research plan?
Yes. Applications are expected to include a well-developed, detailed research plan consistent with a conventional R01 structure.
Is preliminary data expected for applications to this FOA?
Yes. The FOA indicates that applications are expected to include preliminary data, reflecting an emphasis on bold and creative science that is still testable and executable within an R01 framework.
What level of innovation is NIH looking for in this FOA?
The FOA encourages unusually innovative concepts and emphasizes the potential to open new research areas. Transformative or field-shifting ideas appear particularly valued, so long as feasibility is supported through an R01-appropriate plan and evidence.
What are the activity categories associated with this opportunity?
The opportunity is listed under the "Education" and "Health" activity categories.
What CFDA number is associated with this FOA?
The CFDA number listed is 93.279 (Drug Abuse and Addiction Research Programs).
How much total funding is estimated for this FOA?
The total estimated funding listed is $2,000,000.
Is cost sharing or matching required?
No. There is no cost sharing or matching requirement.
When was this FOA posted?
The FOA was posted on March 20, 2013.
What was the application closing date?
The original and current closing date listed is August 1, 2013.
Is this funding opportunity currently open?
No. The listing indicates an archive date of September 1, 2013, which signals that the solicitation is historical rather than currently open.
What types of U.S. organizations are eligible to apply?
Eligibility is broad and includes many U.S.-based entities such as public and private institutions of higher education; nonprofits (including those with and without 501(c)(3) status, with certain distinctions); small businesses and other for-profit organizations (with limits depending on category); and multiple levels of government (state, county, city/township, special district governments, and school districts).
Are tribal entities eligible to apply?
Yes. Eligible applicants include federally recognized tribal governments and tribal organizations that are not federally recognized.
Are organizations serving specific populations explicitly included in eligibility?
Yes. The eligibility list explicitly includes HBCUs, Hispanic-serving institutions, tribally controlled colleges and universities, Alaska Native and Native Hawaiian serving institutions, and AANAPISIS-designated institutions.
Can foreign (non-U.S.) organizations apply?
Yes. The FOA allows participation by non-U.S. entities, including foreign organizations and foreign institutions. It also states that non-domestic components of U.S. organizations are eligible and that foreign components (as defined by NIH policy) are allowed.
Are U.S. territories and possessions eligible?
Yes. The eligibility description includes U.S. territories and possessions, as well as regional organizations.
Where can applicants find the official full FOA text?
The full announcement is available through the NIH Grants Guide link: http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-14-003.html
Who is the contact for access or linking issues related to the FOA?
The contact provided is the NIH Office of Extramural Research (OER) Webmaster: FBOWebmaster@OD.NIH.GOV
What is the simplest way to describe what NIH is trying to fund through this FOA?
This FOA aims to fund unusually forward-looking HIV/AIDS research that is explicitly relevant to drug abuse, using the standard R01 structure to ensure projects are grounded in a concrete plan and supported by preliminary evidence, with clear relevance to HIV prevention and treatment among substance-using populations.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Promoting, Strengthening and Enhancing Disease Prevention by Collaboration with Targeted Stakeholders
Previous opportunity: Wildlife Restoration Grant Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DA 14 003
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DA 14 003) also looked into and applied for these:
| Funding Opportunity |
|---|
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PA 13 157 Funding Number: PA 13 157 Agency: National Institutes of Health Category: Education Health Funding Amount: $175,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21/R33) Apply for PAR 13 158 Funding Number: PAR 13 158 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12) Apply for PAR 13 163 Funding Number: PAR 13 163 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R01) Apply for PA 13 165 Funding Number: PA 13 165 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R15) Apply for PA 13 166 Funding Number: PA 13 166 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R21) Apply for PA 13 167 Funding Number: PA 13 167 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01) Apply for PAR 13 159 Funding Number: PAR 13 159 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Academic Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) Apply for PAR 13 169 Funding Number: PAR 13 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Dissertation Research (R36) Apply for PAR 13 182 Funding Number: PAR 13 182 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Research in Integrative Cancer Biology (U01) Apply for PAR 13 184 Funding Number: PAR 13 184 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Image guided Drug Delivery in Cancer (R01) Apply for PAR 13 185 Funding Number: PAR 13 185 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R01) Apply for RFA MH 14 170 Funding Number: RFA MH 14 170 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R21) Apply for RFA MH 14 171 Funding Number: RFA MH 14 171 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Detection of Pathogen Induced Cancer (DPIC) (R01) Apply for PAR 13 190 Funding Number: PAR 13 190 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications to U01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (U01) Apply for PAR 13 176 Funding Number: PAR 13 176 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Imaging and Biomarkers for Early Cancer Detection (R01) Apply for PAR 13 189 Funding Number: PAR 13 189 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Revision Applications to R01 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (R01) Apply for PAR 13 177 Funding Number: PAR 13 177 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to P50 Awards for Research on Imaging and Biomarkers for Early Cancer Detection (P50) Apply for PAR 13 174 Funding Number: PAR 13 174 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to R01 Awards for Research on Detection of Pathogen Induced Cancer (DPIC) (R01) Apply for PAR 13 172 Funding Number: PAR 13 172 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
| Revision Applications to U01 Awards on Detection of Pathogen Induced Cancer (DPIC) (U01) Apply for PAR 13 173 Funding Number: PAR 13 173 Agency: National Institutes of Health Category: Education Health Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants

Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DA 14 003", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
